August 7, 2025 — Leads & Copy — AbCellera (Nasdaq: ABCL) announced its Q2 2025 financial results and the commencement of a Phase 1 clinical trial for ABCL635, a potential treatment for moderate-to-severe vasomotor symptoms (VMS) associated with menopause.
The company reported a net loss of $34.7 million, compared to $36.9 million in Q2 2024. Revenue totaled $17.1 million, up from $7.3 million year-over-year.
AbCellera’s pipeline has expanded, with ABCL688 advancing into IND-enabling studies. The company has over $750 million in available liquidity.
A conference call and live webcast to discuss the results will be held today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).
Carl Hansen, Ph.D., founder and CEO of AbCellera, emphasized the company’s transition to a clinical-stage biotech firm with the initiation of Phase 1 studies for ABCL635 and ABCL575.
For more information, please visit www.abcellera.com.
Source: AbCellera
